Only about one-third of employers cover GLP-1s to treat obesity, leaving many patients facing prohibitively high drug costs on their own.
Insurance broker Aon says employer-sponsored plans are poised to increase 9.5% next year, to average more than $19,000 per worker.
GLP-1 weight loss drugs are increasingly popular as a treatment for obesity. But a lot of employer-sponsored health plans won’t cover the treatments, especially at small and medium-sized firms.
Historically, it’s been all about building employee loyalty and tax breaks for businesses.
